Monthly Archives: January 2009

Aurobindo Pharma net declines marginally to Rs 41.8 cr in Q3

January 29th, 2009|

Drug maker Aurobindo Pharma Ltd today announced a consolidated net profit of Rs 41.80 crore for the third quarter ended December 31, 2008, marginally lower than the corresponding period a year ago.

Sun Pharma Q3 PAT seen up 43% at Rs 456 cr

January 29th, 2009|

Sun Pharma is to announce its third quarter results. According to CNBC-TV18 estimates, the company's Q3FY09 consolidated net sales are seen up 42% at Rs 1140 crore versus Rs 803 crore, YoY.

CrPC (Amendment) Act 2008 gets Presidents accent

January 29th, 2009|

President gives accent to Law forbidding arrest in offenses carrying upto seven years imprisonment. As reported earlier that the President has granted assent to the law past nearly three week back by the parliament which brings about major changes in the Criminal Procedure Code. This newly enacted law takes away the powers of the police to arrest in cases of alleged offenses which carry a maximum sentence upto seven years of imprisonment.

Fortis Healthcare forays into Mauritius

January 29th, 2009|

Fortis Healthcare, a privately owned hospitals chain promoted by the Singh family, who previously owned Ranbaxy Laboratories, has forayed into the International healthcare market for the first time. Fortis, through one of its wholly owned subsidiary, has joined hands with a diversified Mauritian Industrial Group CIEL, through its subsidiary Novelife, to acquire jointly a controlling stake in Mauritius’s largest private hospital, “Clinique Darné,” now rechristened Fortis Clinique Darné. 

GVK & Crelux set up FBDD platform to deliver lead molecules

January 29th, 2009|

GVK Biosciences and Crelux announced that they have set up a highly robust fragment-based drug discovery platform proven to deliver rapidly, viable lead molecules. Crelux's high performance structural biology technologies together with GVK Bio's mature computer-assisted drug design (CADD) tools and other components of its drug discovery & development engine encompass all steps from challenging targets to novel drug candidates.

Indian guidelines on insulin therapy for primary care physicians launched

January 29th, 2009|

Heralding a new dawn in diabetes management, Indian guidelines on insulin therapy for primary care physicians (PCPs) was launched on the sidelines of APICON 2009 at Greater Noida.

NPPA may allow pharma cos to raise margins

January 29th, 2009|

Taking cognisance of the increase in input cost, the National Pharmaceutical Pricing Authority (NPPA) may allow drug makers to raise their margins in packaging cost of medicines, a government official said.

Paswan to inaugurate SME Centre at NIPER, Mohali on Feb 11

January 29th, 2009|

The Department of Pharmaceuticals much-awaited project of setting up an SME Centre at NIPER, Mohali, to assist the small and medium pharma entrepreneurs will become a reality soon. Union minister for Chemicals and Fertilisers Ramvilas Paswan will inaugurate the SME Centre on February 11.

AIDCOC urges govt to take steps for effective implementation of spurious drugs bill

January 29th, 2009|

The All India Drug Control Officers' Confederation (AIDCOC), the congregation of drug control officers from various states in the country, has urged the government to take adequate steps for successful implementation of stringent rules in the Drugs and Cosmetics (Amendment) Bill 2006 which received president's assent recently.

NPPA begins process for likely hike in CC, PC, PL and PM costs

January 29th, 2009|

The conversion costs, packaging charges and process loss of materials and packaging material costs are likely to be increased to give some relief to the pharma companies as the National Pharmaceutical Pricing Authority (NPPA) has initiated steps to garner inputs from the manufacturers for finalising the norms for the current year.

Guardian launches X-tra Vital food supplements

January 29th, 2009|

Guardian, India's fastest growing retail chain of health, wellness and beauty stores announced the launch of Guardian X-tra Vital for Men and Women in its Guardian Health Care range of private labels.

Watson Pharmaceuticals: Gelnique to benefit from first-to-market status

January 29th, 2009|

Watson Pharmaceuticals's Gelnique is the first gel to be approved by the FDA for the treatment of overactive bladder, and provides an advantageous side-effect profile over current oral anticholinergic and patch treatments. As a result, Datamonitor expects Gelnique to be beneficial for a niche population and to generate $124m in 2016.

Torrent Pharma secures USDFA nod for Lamotrigine

January 29th, 2009|

Ahmedabad-based drug maker Torrent Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) to market Lamotrigine tablet, in the strengths of 25 mg, 100 mg, 150 mg and 200 mg.

Ipsen signs co-promotion pact with Novartis for Exforge in France

January 29th, 2009|

Ipsen has signed an agreement with Novartis for the co-promotion in France of the antihypertensive drug Exforge. Already in partnership with Novartis since 2003 in the area of hypertension, with the co-marketing in France of Nisis & Nisisco, Ipsen's new agreement strengthens the commitment of its French teams to the management of cardiovascular risk factors.

Apotex & IBPL extend pact to develop biosimilar version of pegfilgrastim

January 29th, 2009|

Intas Biopharmaceuticals Limited (IBPL) and Canada-based Apotex Inc have extended their business agreement to develop a biosimilar version of pegfilgrastim, a protein that is used to treat neutropenia, a side effect of cancer chemotherapy. Neupeg, a recombinant pegylated granulocyte colony stimulating factor is already manufactured and marketed in India and other countries by IBPL. 

Deal struck for vector drug delivery to treat ALS

January 29th, 2009|

Therapy Development Institute and Asklepios BioPharmaceutical have entered into a collaboration to develop viral vectors for drug delivery.

What’s ahead for biotech?

January 29th, 2009|

A bleak year of restructuring and refocusing awaits…A number of grim predictions have been made regarding how biotech will fare in the harsh financing environment of 2009. According to G. Steven Burrill of Burrill & Co. (CA, USA), a very different biotech industry to the one of today will be awaiting us at the end of the year.

Pharma Dept to brief companies on measures relating to environmental issues

January 29th, 2009|

After setting up the Environmental Cell to address the concerns of the industry, the department of pharmaceuticals will take inputs from the companies and spell out the programmes to address them in a better way, even as international reports recently suggested high rate of pollution being caused by the pharma firms.

DBT invites proposal from industry for 10th batch of SBIRI scheme

January 28th, 2009|

The Department of Biotechnology (DBT) has called for proposals for its 10th batch of Small Business Innovation Research Initiative (SBIRI) to support innovative, early stage, pre-proof-of-concept research and development and commercialisation efforts of small scale biotechnology companies in the country.

GSK teams up with Path to promote ‘Cevarix’ for national immunization programme

January 28th, 2009|

GlaxoSmithKline Pharmaceuticals GlaxoSmithKline Pharmaceuticals (GSK) will launch its much-awaited vaccine 'Cevarix' for protection against cervical cancer in a month's time.